Relay Therapeutics (RLAY) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

We Think Relay Therapeutics (NASDAQ:RLAY) Needs To Drive Business Growth Carefully
Simply Wall StDec 19 10:58 ET
Relay Therapeutics Insider Sold Shares Worth $500,000, According to a Recent SEC Filing
MT NewswiresDec 18 16:58 ET
Express News | JMP Securities Reiterates Market Outperform on Relay Therapeutics, Maintains $21 Price Target
BenzingaDec 12 09:28 ET
Relay Therapeutics Analyst Ratings
BenzingaDec 12 09:25 ET · Ratings
Jefferies Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $17
Moomoo NewsDec 12 08:31 ET · Ratings
TD Cowen Maintains Relay Therapeutics(RLAY.US) With Buy Rating
Moomoo NewsDec 12 08:31 ET · Ratings

Comments

Jaguar8

Dec 11 05:03

NEWS

$Relay Therapeutics (RLAY.US)$
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
Relay Therapeutics (RLAY) announced updated interim data for RLY-2608, showing an 11.4-month median progression-free survival in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at the recommended Phase 2 dose. The study demonstrated a 39% confirmed objective response rate ...

1

5

Trytosaveabit

Dec 11 05:01

Update

$Relay Therapeutics (RLAY.US)$ Reuters· just
Relay Therapeutics Announces Updated Interim Data for Rly-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

2

Jaguar8

Dec 9 15:07

NEWS

$Relay Therapeutics (RLAY.US)$
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Relay Therapeutics (RLAY) announced it will present updated clinical data for RLY-2608 in combination with fulvestrant for treating PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer at the San Antonio Breast Cancer Symposium (December 10-13, 2024). The presentation, titled 'Efficacy of RLY-2608, a mutant-se...

1

Jaguar8

Dec 3 16:27

🟢Watchlist Wednesday, December 4. NFA. Check on my previous watchlist. Those without ✅ means they can have delayed market reaction.

Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...

34

7

6

Jaguar8

Dec 3 07:21

NEWS

$Relay Therapeutics (RLAY.US)$
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
Relay Therapeutics (RLAY) and Elevar Therapeutics have announced an exclusive global licensing agreement for lirafugratinib, a potential best-in-class FGFR2 inhibitor for treating FGFR2-driven cholangiocarcinoma and other solid tumors. Under the agreement, Elevar receives worldwide development and c...

RLAY Relay Therapeutics

Trade Overview

Capital Trend

News

Comments